Tirzepatide · 3 min read
List price is a fiction almost nobody pays. The real 2026 cash landscape — $215 compounded, $299–$449 LillyDirect, ~$350 TrumpRx, ~$50 new Medicare copays — priced in words with conditions attached.
List price is a fiction almost nobody pays. The real 2026 cash landscape — $215 compounded, $299–$449 LillyDirect, ~$350 TrumpRx, ~$50 new Medicare copays — priced in words with conditions attached.
Tirzepatide's list price — over a thousand dollars a month — is a fiction almost nobody pays in 2026. The real cash market has four tiers, and the honest answer to "what does tirzepatide cost without insurance" is a range from about $215 to $449 a month depending on which tier you use and which dose you need.
FDA-approved Zepbound through LillyDirect costs $299 a month for the 2.5 mg starter vial, $399 at 5 mg, and $449 for every dose from 7.5 through 15 mg — and since March 2026 the same $299–$449 applies to KwikPens at retail pharmacies including Walmart, so mail order is no longer required. The catch is the cadence: the Self Pay Journey pricing requires refilling within a 45-day window on the higher doses, and a lapsed refill reprices at $599 to $1,049 until you re-enroll. TrumpRx, launched in February 2026, lists Zepbound at roughly $350 a month. For most maintenance-dose cash payers, $449 is the brand number to budget.
Verified compounded tirzepatide in our database runs $215 to $597 a month all-in at the 10 mg basis — NexLife at the floor ($215 flat, no membership), a middle band around $278–$299 (IVIM and Mochi all-in, ShedRx at tier, SkinnyRx flat), and split-billing outliers reaching $597 (LifeMD). Prepaid terms cut deeper: Found's twelve-month plan works out to $169 a month and NexLife's to $186, both paid up front. Compounded product is not FDA-approved, and its 2026 legal footing is narrower and contested — priced fully in our compounded ranking and explained in the legal-status guide.
Two 2026 developments change the "no insurance" math for specific groups. Medicare Part D began covering Zepbound for certain patients in mid-2026 at roughly a $50 monthly copay — the first Medicare obesity-drug coverage, tied to the manufacturers' pricing deals with the administration. And Zepbound's sleep-apnea indication opens medical-necessity pathways some commercial plans honor even when they exclude weight loss. If you have any coverage at all, exhaust these before paying cash.
Two traps close out the map. "Research use" tirzepatide from gray-market peptide sites is unregulated powder with no prescription, no pharmacy, and no legal personal-use pathway — the reported quality failures are exactly what you would expect, and no price justifies it. And within legitimate programs, the classic distortions apply: starter-dose figures presented as standing rates, prepaid annual math presented as monthly, and medication prices that omit mandatory memberships. Every figure above carries its condition in the sentence; every program's full record is in the pricing database.
Realistically $215–$449: verified compounded programs run $215–$597 all-in (most $215–$299), and FDA-approved Zepbound runs $299–$449 through LillyDirect or about $350 via TrumpRx. List price (~$1,086+) is not what cash payers actually pay in 2026.
LillyDirect self-pay: $299 for the 2.5 mg starter vial and $449 at maintenance doses, with retail KwikPen parity since March 2026 — provided you keep the 45-day refill cadence. Certain Medicare patients now pay about $50 under mid-2026 Part D coverage.
For tirzepatide specifically, manufacturer self-pay pricing has generally undercut discount-card retail pricing since the late-2025 price cuts. Check both, but LillyDirect's $299–$449 is the benchmark to beat.